Oxfordshire is one of four counties where paramedics will make home visits to give babies antibody jabs.

Paramedics are to visit babies in their homes to provide a new antibody jab which will protect them against a potentially dangerous respiratory virus, as part of a multi-national study.

South Central Ambulance Service (SCAS) is the first ambulance service in the country to offer the service to provide the vaccine against Respiratory Syncytial Virus (RSV).

Read more: Live updates: Lane blocked after crash

RSV is one of the leading causes of hospitalisation in all infants worldwide, affecting 90 per cent of children before the age of two.

It often causes only mild illness like a cold but, for some babies, it leads to more severe lung problems such as bronchiolitis and pneumonia with a resurgence being experienced since the lifting of Covid-19 restrictions.

Now as part of a study called Harmonie, which will involve 20,00 infants across the UK, France and Germany, SCAS paramedics will be visiting families across Berkshire, Buckinghamshire, Oxfordshire and Hampshire to give the jab to babies under 12 months old.

Martina Brown, research and clinical audit manager at SCAS, said: “We are extremely proud to be the first ambulance trust to utilise our dedicated research paramedics and nurses to immunise patients against this potentially dangerous winter virus.

“Our involvement means we are able to offer an opportunity to be involved to those families who are unable to travel to medical centres by visiting them at home and, given the cascading effect of RSV on ambulance services and the wider NHS, the potential positive impact of this pioneering study could be significant.”

Dr Simon Drysdale, consultant paediatrician in infectious diseases at St George’s University Hospitals NHS Foundation Trust and co-chief investigator of the study, said: “RSV is a common respiratory virus which affects nearly all children before the age of two.

“For most children it causes a mild illness like a cold, however, it can lead to more severe lung problems for some, such as bronchiolitis and pneumonia.

“The Harmonie study is looking at how strongly babies can be protected from illness caused by RSV infection through a single antibody dose, which acts in the same way as antibodies in our own bodies but is targeted specifically to fight RSV.”

The trial is a collaboration between Sanofi, its partner AstraZeneca and the National Institute for Health and Care Research (NIHR) and will run until March next year.

The NIHR fund, enable and deliver world-leading health and social care research that improves people’s health and wellbeing, and promotes economic growth.

 

Read more from this author

This story was written by Matthew Norman, he joined the team in 2022 as a Facebook community reporter.

Matthew covers Bicester and focuses on finding stories from diverse communities.

Get in touch with him by emailing: Matthew.norman@newsquest.co.uk

Follow him on Twitter: @OxMailMattN1

A message from our Editor

Thank you for reading this story and supporting the Oxford Mail.

If you like what we do please consider getting a subscription for the Oxford Mail and in return we’ll give you unrestricted access with less adverts across our website from the latest news, investigations, features, and sport.

Follow us on Facebook, Twitter, Instagram and Tik Tok for more. 

You can also join the conversation in our Facebook groups: stay ahead of traffic alerts here, keep up to date with the latest from court here, share your favourite memories of Oxford here, get your daily dose of celebrity news here and take some time out with news that will make you smile. 

If you’ve got a story for our reporters, send us your news here. You can also list an event for free here.